Atlas: full composition and an honest evidence review

A man standing calmly after training on a sunlit stone terrace beside an olive tree

Atlas is a named combination of CJC-1295, ipamorelin, tesamorelin, and IGF-1 LR3. Three components act upstream of growth hormone release and the fourth is an insulin-like growth factor analogue that acts downstream. No controlled human study of this combination was identified, and the presence of IGF-1 LR3 raises specific safety questions that this page states directly.

Composition

  • cjc-1295
  • ipamorelin
  • tesamorelin
  • igf-1-lr3

Overview

Atlas is unusual among these combinations because it pairs substances that stimulate the body's own growth hormone release with a direct analogue of insulin-like growth factor 1. That means it acts at two ends of the same axis simultaneously. Upstream stimulation is self-limited by feedback. A direct IGF-1 analogue is not. That difference is the most important thing on this page and is why the safety discussion here is longer than for the other growth hormone groupings.

Why these are grouped

The stated rationale is to raise activity across the whole axis rather than at one point. That rationale is mechanistic. No published study evaluated whether combining upstream stimulation with a downstream analogue is more useful, or simply removes the feedback that normally limits the system.

What each ingredient contributes

cjc-1295

A releasing hormone analogue studied for extended signalling. Human data are limited to small early pharmacology work.

ipamorelin

A secretagogue acting at a different receptor, included for pathway breadth rather than proven added value.

tesamorelin

The component with the most developed human trial record, in an FDA-approved indication unrelated to general use.

igf-1-lr3

A modified insulin-like growth factor analogue used almost exclusively as a laboratory research reagent. It acts downstream of the other three and carries the most serious open safety questions in this grouping.

Combination evidence

  • No published human trial of the Atlas combination was identified.
  • No published data describe what happens when upstream growth hormone stimulation and a downstream IGF-1 analogue are used together in people.
  • The absence of data here is not a neutral finding. It means an important safety question has not been answered.

Tesamorelin has approval-grade human data in a narrow indication. CJC-1295 has small human pharmacology studies. Ipamorelin is largely preclinical. IGF-1 LR3 is sold as a research reagent and is not an approved medicine anywhere in the United States, with human safety data that do not exist in any adequate form.

Preclinical rationale

  • Growth hormone acts in part through IGF-1, which is the mechanistic argument offered for including a direct analogue.
  • The same mechanism explains why the combination is difficult to reason about: normal feedback limits how much IGF-1 the body produces, and a direct analogue bypasses that limit.

What is not established

  • Whether combining upstream and downstream agents is safe in people.
  • What sustained IGF-1 receptor activation does over months in healthy adults.
  • Whether any benefit attributed to this grouping exceeds what a single component would produce.
  • Any long-term risk relationship for people with a personal or family cancer history.

Questions to discuss with a physician

  • Given my family history, is IGF-1 signalling something I should be adding to at all?
  • What is the argument for a downstream analogue on top of upstream stimulation?
  • How would hypoglycaemia risk be managed and monitored?
  • Is there a single-component option that addresses my goal with better evidence?
  • What would make you stop?

This page is educational. Nothing here can be ordered, and nothing here is a prescription or medical advice. Compounded preparations are not FDA-approved. To ask about current availability, visit goal.md/peptides/connect or call or text 314-907-3103.

Medically reviewed by Michael Fitch, MD, MD. Last reviewed 2026-08-15.